Early cellular responses in the peritoneal cavity of mice to antitumor immunomodulators.
The early cellular responses to antitumor immunomodulators and conventional inducers, especially the polymorphonuclear leukocyte (PMN) responses, were examined in the peritoneal cavity of mice to investigate their effect on primary defense mechanisms. Immunomodulators were classified into 5 groups in terms of PMN response on the basis of its duration (declining or persistent) and extent (high or low induction): 1) TAK (beta-1,3-glucan)-type (high, persistent), 2) lentinan-type (high, declining), 3) yeast mannan-type (low, declining), 4) LPS (lipopolysaccharide)-type (low, persistent), 5) others (no effect). Since the general PMN response is of the declining type, the persistence of PMN with TAK- and LPS-type immunomodulators is a characteristic of the PMN-inducing activity. With respect to the extent, TAK- and lentinan-type immunomodulators induced larger numbers of PMN and macrophages than conventional inducers. These results suggest that some types of immunomodulators have effects on the early host-defense mechanism. From the viewpoint of the general self-defense mechanism we also compared these PMN responses with those to bacteria and to tumor inoculation, and the properties of substances inducing high PMN response, i.e., those with the quality of "foreignness," are discussed.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000276:immunology; D000190:Actinomyces; D000276:Adjuvants, Immunologic / Q000276:immunology*; D000818:Animals; D001500:BCG Vaccine / Q000276:immunology; D003208:Concanavalin A; D005936:Glucans / Q000276:immunology; D007111:Immunity, Cellular; D008114:Liver Neoplasms, Experimental / Q000276:immunology / Q000473:pathology; D008264:Macrophages / Q000276:immunology; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000473:pathology; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000473:pathology; D009504:Neutrophils / Q000276:immunology*; D010529:Peritoneal Cavity / Q000276:immunology; D010844:Picibanil / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D047071:beta-Glucans
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D005936:Glucans; D011135:Polysaccharides, Bacterial; D047071:beta-Glucans; D003208:Concanavalin A; D010844:Picibanil; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C033363:beta-1,3-glucan